Nanocarrier-mediated cancer therapy with cisplatin: A meta-analysis with a promising new paradigm
Document Type
Article
Publication Date
4-1-2024
Abstract
Aims: Cisplatin is a frontline chemotherapeutic utilized to attenuate multiple cancers in the clinic. Given its side -effects, a new cisplatin formulation which could prevent cytotoxicity, metabolic deficiencies and metastasis is much needed. This study investigates whether nanocarriers can provide a better mode of drug delivery in preclinical cancer models seeking a potent anticancer therapeutic agent. Materials and methods: The PubMed database was searched, and 242 research articles were screened from which 94 articles qualified for selection from those published by December 31, 2023 and the data was synthesized using the Review Manager software. Key findings: Cisplatin encapsulated as a nanomedicine confirmed the versatility of nanocarriers in significantly diminishing cancer cell viability, half maximal inhibitory concentration, tumour volume, biodistribution of platinum in tumours and kidney; at p < 0.00001 and a 95% confidence interval. Significance: An estimated 19.3 million global cancer incidence is reported with 50% mortality worldwide for which nanocarrier-mediated cisplatin therapy is most promising. Our findings offer new vistas for future cancer treatment when combined with chemo-immunotherapy that utilizes the recently advanced nanozymes.
Keywords
Cisplatin, Nanocarriers, Nanotechnology, Nanomedicine, Meta-analysis, Cancer cell viability, Tumour volume, IC50, Biodistribution of platinum in vital organs
Divisions
fac_med
Funders
Research Training Programme (RTP) Scholarship Australian Government
Publication Title
Heliyon
Volume
10
Issue
7
Publisher
Elsevier
Publisher Location
50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA